EYPT
EyePoint Pharmaceuticals Inc

8,661
Loading...
Loading...
News
all
press releases
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
EyePoint Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Latest Ratings for EYPT DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy May 2021HC Wainwright & Co.MaintainsBuy Jan 2021Cantor FitzgeraldInitiates Coverage OnOverweight View More...
Benzinga·1y ago
News Placeholder
Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT
Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results
Stocktwits·1y ago
News Placeholder
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
read more...
Benzinga·1y ago
News Placeholder
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
EyePoint Pharmaceuticals reveals Phase 2 PAVIA trial results for Duravyu in non-proliferative diabetic retinopathy. Positive data showcases Duravyu's efficacy and safety profile. read more...
Benzinga·1y ago
News Placeholder
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O...
Globe Newswire·1y ago
News Placeholder
EyePoint Pharmaceuticals (EYPT, $20.27) RSI Indicator left the oversold zone on April 01, 2024
This is a signal that EYPT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·1y ago
News Placeholder
EyePoint Pharmaceuticals (EYPT, $20.27) Aroon Indicator entered a Downtrend on April 01, 2024.
For the last three days, A.I.dvisor has detected that EYPT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Tickeron - Stocks·1y ago
News Placeholder
More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shares have had a horrible month, losing 26% after a relatively good...
Simply Wall St·1y ago

Latest EYPT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.